← CORCEPT THERAPEUTICS INC CORT
Market Price
$114.42
Market Cap
$11.86B
P/E Ratio
139.54
Revenue (FY 2025)
↑12.8% YoY
$761.41M
3-Yr CAGR: 23.7%
Net Income
↓-29.4% YoY
$99.65M
Net Margin: 13.1%
Free Cash Flow
↓-27.6% YoY
$141.78M
FCF Yield: 1.20%
EPS (Diluted)
↓-33.3% YoY
$0.82
Basic: $0.95
Return on Equity
Efficiency
15.4%
ROA: 245.1%
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (CORT)
All monetary values in millions ($M)| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2016 | $23.8M | — | $21.8M | $8.1M | — | $0.07 | — | $18.4M | $18.2M | — |
| FY 2017 | $53.3M | +123.8% | $49.7M | $129.1M | +1,486.3% | $1.04 | +1,385.7% | $60.9M | $60.5M | +232.6% |
| FY 2018 | $251.2M | +371.6% | $246.0M | $75.4M | -41.6% | $0.60 | -42.3% | $115.7M | $115.4M | +90.6% |
| FY 2019 | $306.5M | +22.0% | $301.0M | $94.2M | +24.9% | $0.77 | +28.3% | $136.1M | $135.0M | +17.0% |
| FY 2020 | $353.9M | +15.5% | $348.3M | $106.0M | +12.6% | $0.85 | +10.4% | $152.0M | $150.7M | +11.6% |
| FY 2021 | $366.0M | +3.4% | $360.7M | $112.5M | +6.1% | $0.89 | +4.7% | $167.9M | $167.4M | +11.1% |
| FY 2022 | $401.9M | +9.8% | $396.5M | $101.4M | -9.9% | $0.87 | -2.2% | $120.3M | $119.9M | -28.4% |
| FY 2023 | $482.4M | +20.0% | $475.9M | $106.1M | +4.7% | $0.94 | +8.0% | $127.0M | $126.9M | +5.8% |
| FY 2024 | $675.0M | +39.9% | $664.2M | $141.2M | +33.0% | $1.23 | +30.9% | $198.1M | $195.9M | +54.4% |
| FY 2025 | $761.4M | +12.8% | $748.4M | $99.7M | -29.4% | $0.82 | -33.3% | $142.0M | $141.8M | -27.6% |
Valuation
Market Price
$114.42
Market Cap
$11.86B
Enterprise Value
N/A
P/E Ratio
139.54
P/B Ratio
18.96
FCF Yield
1.20%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
98.30%
Operating Margin
5.88%
Net Margin
13.09%
Return on Equity (ROE)
15.38%
Return on Assets (ROA)
245.10%
Asset Turnover
18.73x
Revenue 3-Yr CAGR
23.74%
Financial Health & Liquidity
Current Ratio
0.45
Cash Ratio
1.33
Debt / Equity
N/A
Debt / Assets
N/A
Cash & Equivalents
$120.50M
Total Debt
N/A
Book Value / Share
$6.03
Cash Flow Efficiency
Operating Cash Flow
$142.00M
Capital Expenditures (CapEx)
$211.00K
Free Cash Flow
$141.78M
OCF / Revenue
18.65%
FCF / Revenue
18.62%
FCF 3-Yr CAGR
5.74%
Per Share Metrics
EPS (Diluted)
$0.82
EPS (Basic)
$0.95
Dividends / Share
N/A
Book Value / Share
$6.03
EPS YoY Growth
-33.33%
Balance Sheet (FY 2025)
Total Assets
$40.66M
Total Liabilities
$90.60M
Stockholders' Equity
$647.80M
Current Assets
$40.66M
Current Liabilities
$90.60M